[ Price : $8.95]
Federal Register Notice: FDA determines the regulatory review period for Bristol-Myers Squibbs Onglyza for the purpose of patent e...[ Price : $8.95]
FDA accepts for filing and gives priority review status to Alimera Sciences Illuvien NDA.[ Price : $8.95]
A recent online news report about a pending Supreme Court case wrongly suggests the high court is reviewing FDA adverse event repo...[ Price : $8.95]
In its latest batch of Warning Letters, FDA cites Alphatec Spine, Baxter Healthcare, BioVeda, Diasol, Laboratorios, Patrick Nemech...[ Price : $8.95]
Federal Register Notice: FDA seeks comments on a study that is testing different ways of presenting benefit and risk information i...[ Price : $8.95]
Federal Register Notice: FDA determines the regulatory review period for Pfizers Pristiq for the purpose of patent extension.[ Price : $8.95]
Federal Register Notice: FDA releases a draft guidance on civil money penalties for tobacco retailers for violators of the FDA&C A...[ Price : $8.95]
Members of Congress say a new GAO reports shows that FDA needs to do more to ensure that non-inferiority trials adequately evaluat...